We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Laureate and Iconic Announce Immunoprotein Manufacturing Agreement
News

Laureate and Iconic Announce Immunoprotein Manufacturing Agreement

Laureate and Iconic Announce Immunoprotein Manufacturing Agreement
News

Laureate and Iconic Announce Immunoprotein Manufacturing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Laureate and Iconic Announce Immunoprotein Manufacturing Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Laureate Pharma, Inc. has announced that it has entered into a biopharmaceutical manufacturing agreement with Iconic Therapeutics, Inc. for cGMP manufacture of hI-con1, a "bi-functional immunoprotein."

"Iconic Therapeutics has a unique bi-functional immunoprotein for the treatment of wet adult macular degeneration and cancer and we are very pleased to be working with them on this exciting product," said Robert J. Broeze, Ph.D., President and Chief Executive Officer of Laureate Pharma.

"We look forward to a productive and successful relationship with Iconic Therapeutics."

"Our partnership with Laureate Pharma is an important aspect of our manufacturing strategy and our plans to initiate clinical evaluation of hI- con1 protein," said Michael I. Sherman, Ph.D., President of Iconic Therapeutics.

hI-con1™ protein is a "bi-functional immunoprotein," so called because it contains two functional domains connected by a "hinge," and each portion has a specific role to play in the protein's activity.

One domain of the hI- con1™ is a "homing sequence" that targets pathological cells whereas the other portion, the "effector sequence," is the part of an antibody that signals the immune system to destroy the targeted cells.

In addition to potential therapeutic utility in wet adult macular degeneration and many solid cancers, hI-con1™ has the prospect of being useful in treating other diseases as well.

Advertisement